Biochemical markers of bone remodeling;Marqueurs biochimiques du remodelage osseux

Revue du Rhumatisme (Edition Francaise)

Volumn 73, Issue 8, 2006, Pages 804-806

  Cohen Solal, Martine ^a   de Vernejoul, Marie Christine ^a  

^a CENTRE VIGGO PETERSEN   (France)

Author keywords

Biochemical markers; Bone formation; Osteoporosis; Resorption

Indexed keywords

EID: 33748790111     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rhum.2006.05.003     Document Type: Short Survey

References (20)

1. Hannon R.A., and Eastell R. Biochemical markers of bone turnover and fracture prediction. J. Br. Menopause Soc. 9 (2003) 10-15
2. Bonnick S.L., and Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?. Am. J. Med. 119 Suppl (2006) S25-S31
3. Garnero P., Hausherr E., Chapuy M.C., Marcelli C., Grandjean H., Muller C., et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J. Bone Miner. Res. 11 (1996) 1531-1538
4. Garnero P., Dargent-Molina P., Hans D., Schott A.M., Breart G., Meunier P.J., et al. Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos. Int. 8 (1998) 563-569
5. Wasnich R.D., and Miller P.D. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J. Clin. Endocrinol. Metab. 85 (2000) 231-236
6. Cummings S.R., Karpf D.B., Harris F., Genant H.K., Ensrud K., LaCroix A.Z., et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am. J. Med. 112 (2002) 281-289
7. Hochberg M.C., Greenspan S., Wasnich R.D., Miller P., Thompson D.E., and Ross P.D. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J. Clin. Endocrinol. Metab. 87 (2002) 1586-1592
8. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 13 (1999) 1344-1352
9. Melton III L.J., Khosla S., Atkinson E.J., O'Fallon W.M., and Riggs B.L. Relationship of bone turnover to bone density and fractures. J. Bone Miner. Res. 12 (1997) 1083-1091
10. Seibel M.J., Naganathan V., Barton I., and Grauer A. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J. Bone Miner. Res. 19 (2004) 323-329
11. Delmas P.D., Li Z., and Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J. Bone Miner. Res. 19 (2004) 330-337
12. Bauer D.C., Black D.M., Garnero P., Hochberg M., Ott S., Orloff J., et al. Fracture Intervention Trial Study Group.Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J. Bone Miner. Res. 19 (2004) 1250-1258
13. Eastell R., Barton I., Hannon R.A., Chines A., Garnero P., and Delmas P.D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J. Bone Miner. Res. 18 (2003) 1051-1056
14. Bjarnason N.H., Sarkar S., Duong T., Mitlak B., Delmas P.D., and Christiansen C. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos. Int. 12 (2001) 922-930
15. Garnero P., Shih W.J., Gineyts E., Karpf D.B., and Delmas P.D. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J. Clin. Endocrinol. Metab. 79 (1994) 1693-1700
16. Chesnut III C.H., Bell N.H., Clark G.S., Drinkwater B.L., English S.C., Johnson Jr. C.C., et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am. J. Med. 102 (1997) 29-37
17. Black D.M., Greenspan S.L., Ensrud K.E., Palermo L., McGowan J.A., and Lang T.F. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349 (2003) 1207-1215
18. Chen P., Satterwhite J.H., Licata A.A., Lewiecki E.M., Sipos A.A., Misurski D.M., et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J. Bone Miner. Res. 20 (2005) 962-970
19. Delmas P.D., Licata A.A., Reginster J.Y., Crans G.G., Chen P., Misurski D.A., et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone 39 (2006) 237-243
20. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 29 (2004) 459-468